CD33 and neoplasm: To further confirm this potential of the galectin-1-specific inhibitory peptide (anginex) in vivo, NSG mice established with 5 × 105 U937 tumor cells received a single dose of 8 × 105 CD33 CAR T cells followed by intraperitoneal injection of the anginex and control peptide (10 mg/kg (body weight) every 3 days) (Fig. 8B).